Clinical Trials · NCT03720886
G56W1 in Women With Postmenopausal Osteoporosis
- Phase
- Phase 1/Phase 2
- Recruitment status
- Unknown
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Enrollment
- 148
- Start date
- Oct 2018
- Locations
- 9 sites, China
- Primary endpoint
- The percentage change in bone density of the lumbar spine ( L1-4 ) from baseline to 24 weeks after treatment